Patents by Inventor Mark Heipel

Mark Heipel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1
    Patent number: 10906965
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 2, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1
    Publication number: 20190119367
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: October 25, 2018
    Publication date: April 25, 2019
    Applicant: Novo Nordisk A/S
    Inventors: Vibeke Westphal STENNICKE, Christine Brender READ, Joseph Leon KUIJPER, Xiaoting TANG, Mark HEIPEL, Siv Annegrethe HJORTH
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 10150809
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: December 11, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • ANTIBODIES THAT BIND PEPTIDOGLYCAN RECOGNITION PROTEIN 1
    Publication number: 20180016326
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: April 10, 2017
    Publication date: January 18, 2018
    Inventors: Vibeke Westphal STENNICKE, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Antibodies that bind peptidoglycan recognition protein 1
    Patent number: 9663568
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 30, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joseph Leon Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • Antibodies That Bind Peptidoglycan Recognition Protein 1
    Publication number: 20150018528
    Abstract: Disclosed herein is a method for identifying TREM-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of TREM-1's ligand. Antibodies that reduce or block TREM-1 activation may be identified and selected using this method. Antibodies that bind to TREM-1's ligand and reduce TREM-1 activity may be suitable for use as medicaments.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 15, 2015
    Inventors: Vibeke Westphal Stennicke, Christine Brender Read, Joe Kuijper, Xiaoting Tang, Mark Heipel, Siv Annegrethe Hjorth
  • METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY
    Publication number: 20070178063
    Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
    Type: Application
    Filed: October 6, 2006
    Publication date: August 2, 2007
    Inventors: Wayne Kindsvogel, Steven Hughes, Richard Holly, Christopher Clegg, Donald Foster, Rebecca Johnson, Mark Heipel, Pallavur Sivakumar
  • METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY
    Publication number: 20070122382
    Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
    Type: Application
    Filed: October 6, 2006
    Publication date: May 31, 2007
    Inventors: Wayne Kindsvogel, Steven Hughes, Richard Holly, Christopher Clegg, Donald Foster, Rebecca Johnson, Mark Heipel, Pallavur Sivakumar
  • METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY
    Publication number: 20070048264
    Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
    Type: Application
    Filed: October 6, 2006
    Publication date: March 1, 2007
    Inventors: Wayne Kindsvogel, Steven Hughes, Richard Holly, Christopher Clegg, Donald Foster, Rebecca Johnson, Mark Heipel, Pallavur Sivakumar
  • Methods of treating cancer using IL-21 and monoclonal antibody therapy
    Publication number: 20050265966
    Abstract: Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies.
    Type: Application
    Filed: May 20, 2005
    Publication date: December 1, 2005
    Inventors: Wayne Kindsvogel, Steven Hughes, Richard Holly, Christopher Clegg, Donald Foster, Rebecca Johnson, Mark Heipel, Pallavur Sivakumar